title: Concurrent radiotherapy and chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
abstract: BACKGROUND
  Concurrent chemoradiation is the standard treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC).The present study was carried out to assess the feasibility and efficacy of low-dose gemcitabine as a radiosensitizer when used during radical therapeutic management of patients with locally advanced HNSCC.
  
  
  METHODS
  Fifty-two patients with locally advanced HNSCC (stage III, 50%; stage IVa, 50%) were enrolled during the period from July 2008 to December 2010. All received a course of radiotherapy (70 Gy over 7 weeks) concurrent with weekly infusions of gemcitabine at 50 mg/m(2).
  
  
  RESULTS
  All patients were available for toxicity and response. Severe mucositis (grade 3-4) was observed in 76% of patients. Severe hematological toxicity was uncommon. Xerostomia was the most common late toxicity in 34 patients (65.4%). The rate of complete and partial response rate was 67.3% and 21.1%, respectively, with an overall response rate of 88.45%. Two years progression-free survival and disease-free survival were 46% and 38.46%, respectively.
  
  
  CONCLUSIONS
  Using low-dose gemcitabine concurrent with radiotherapy maintains high response rate with low systemic toxicity, in spite of severe mucositis in a high percentage of patients.
authors.affiliation: Clinical Oncology department, Sohag University, Sohag, Egypt. sayedmostafa09@gmail.com
authors.forename: Elsayed M
authors.initials: EM
authors.lastname: Ali
authors.forename: Ahmad G
authors.initials: AG
authors.lastname: Abdelraheem
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine
references.citation: J Clin Oncol. 2001 Feb 1;19(3):792-9
references.pmid: 11157033
references.citation: Semin Oncol. 1994 Jun;21(3):349-58
references.pmid: 8209266
references.citation: Afr Health Sci. 2008 Sep;8(3):149-55
references.pmid: 19357741
references.citation: J Clin Oncol. 2000 Apr;18(8):1652-61
references.pmid: 10764425
references.citation: J Clin Oncol. 1998 Apr;16(4):1318-24
references.pmid: 9552032
references.citation: Ann Oncol. 2004 Feb;15(2):301-6
references.pmid: 14760126
references.citation: Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):867-72
references.pmid: 8598364
references.citation: Ann Oncol. 2005;16 Suppl 2:ii258-64
references.pmid: 15958469
references.citation: Lancet Oncol. 2001 Sep;2(9):533-43
references.pmid: 11905707